Immunogenicity and safety of MF59-adjuvanted H5N1 pandemic influenza vaccine in healthy infants and children: a phase 2 randomized, observer-blind, multicenter study

Read full text Summarise with VIRAT
Authors: Airi Põder, Mitzi Trinidad‐Aseron, Esther van Twuijver, Eve M. Versage, Matthew J. Hohenboken
Cited by: 0
References: 19

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Zoonotic influenza pandemics can cause substantial morbidity and mortality, especially in children. The present study evaluated the immunogenicity and safety of six formulations of an MF59-adjuvanted H5N1 vaccine (aH5N1). In this phase 2, dose-ranging study, children aged 6 months to

Fields of Study & Subjects

Influenza Virus Research Studies Bacterial Infections and Vaccines Immunotherapy and Immune Responses

Publication details

Journal / source
Vaccine
Volume
80
Pages
128504–128504
Publication date
26 March 2026
Language
EN